Maryam S. Yazdy: From FDA to BeiGene – Embracing a New Chapter
Maryam S. Yazdy, Senior Physician on the Lymphoma team in the Division of Hematologic Malignancies 2 at the Center for Drug Evaluation and Research (CDER), shared a post on LinkedIn:
“From FDA to BeiGene: Embracing a New Chapter.
I’m excited to share that I’ll be starting a new position as Senior Medical Director, Clinical Development at BeiGene!
This is a bittersweet moment as I also announce that I’ll be leaving my role at the FDA, where I’ve been part of the Division of Hematologic Malignancies 2 (DHM2) in the Center for Drug Evaluation and Research (CDER).
Deep Gratitude for My FDA Journey:
Working at DHM2/CDER has been an incredible journey and a true privilege. I want to express my deep gratitude to the amazing colleagues, supportive team leaders, and our dedicated division director who made my experience so meaningful. I’ve learned so much from each of you, and I’m proud of the work we’ve done together to advance therapies for patients. The progress we made – especially in the fight against lymphomas and chronic lymphocytic leukemia (CLL) – is something I will always cherish.
While it’s not easy to say goodbye to my FDA family, I carry forward all the lessons and inspiration from my time at DHM2. Thank you to everyone at the FDA who has supported and encouraged me – your mentorship and camaraderie have meant the world to me.
Looking Ahead to BeiGene:
I am thrilled for the opportunity to join the talented team at BeiGene and contribute to their mission of developing innovative cancer therapies. In this new role, I’ll continue to pursue our shared passion for helping patients by advancing treatments and ultimately finding a cure for lymphomas and CLL. This mission remains close to my heart, and I’m energized to tackle the challenges and opportunities that lie ahead in the biotech industry.
I’m excited to embark on this next chapter at BeiGene, and I look forward to staying connected and continuing our important work from this new vantage point.
Onwards and upwards!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023